FDA/CDC

FDA delays action on Pfizer vaccine for kids under 5


 

The Food and Drug Administration said Feb. 11 it would delay a decision on authorizing the use of the Pfizer vaccine for younger children until data on the effects of three doses is available.

Peter Marks, MD, director of the FDA’s Center for Biologics Evaluation and Research, said the plan for a meeting the week of Feb. 14 of the FDA’s Vaccines and Related Biological Products Advisory Committee was to “understand if two doses would provide sufficient protection to move forward.”

Pfizer has asked the FDA to authorize the use of its mRNA vaccine for children under the age of 5. But, Dr. Marks said, “in looking through the data we realized now … that at this time it makes sense for us to wait until we have the data of the evaluation of a third dose before taking action.”

FDA icon
In response to a question, Dr. Marks said the decision should be reassuring for parents and the public.

“If we feel something doesn’t meet (our) standard, we can’t go forward,” he said. “Rather than an issue of having anyone question the process, I hope this reassures people that the process has a standard.”

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, predicted in January that the Pfizer vaccine for younger kids could be available this month. But, he also predicted three doses would be required.

Pfizer announced in mid-December that it planned to submit data to the FDA during the first half of 2022 if the three-dose study was successful. At that time, Pfizer said it didn’t identify any safety concerns with the 3-microgram dose for children ages 6 months to 4 years, which is much lower than the 30-microgram dose given to adults.

A version of this article first appeared on WebMD.com.

Recommended Reading

Long COVID is real, and many real questions remain
MDedge Dermatology
FDA grants full approval to Moderna COVID-19 vaccine
MDedge Dermatology
Omicron subvariant 1.5 times more contagious than Omicron
MDedge Dermatology
Antibody mix may prevent COVID symptoms in some asymptomatic people
MDedge Dermatology
Guttate Psoriasis Following COVID-19 Infection
MDedge Dermatology
Boosted Americans 97 times less likely to die of COVID-19 than unvaccinated
MDedge Dermatology
Oral Isotretinoin for Acne in the US Military: How Accelerated Courses and Teledermatology Can Minimize the Duty-Limiting Impacts of Treatment
MDedge Dermatology
Q&A: Long COVID symptoms, management, and where we’re headed
MDedge Dermatology
Scientists see hope in new therapy for COVID-19 brain fog patients
MDedge Dermatology
Omicron death rate higher than during Delta surge
MDedge Dermatology